UNLABELLED: Ginkgo biloba has been reported to improve cognitive function in older adults and patients with Alzheimer's disease and multi-infarct dementia. We conducted an open-label phase II study of this botanical product in symptomatic irradiated brain tumor survivors. Eligibility criteria included: life expectancy ≥30 weeks, partial or whole brain radiation ≥6 months before enrollment, no imaging evidence of tumor progression in previous 3 months, or stable or decreasing steroid dose, and no brain tumor treatment planned while on study. The Ginkgo biloba dose was 120 mg/day (40 mg t.i.d.) for 24 weeks followed by a 6-week washout period. Assessments performed at baseline, 12, 24 (end of treatment), and 30 weeks (end of washout) included KPS, Functional Assessment of Cancer Therapy-Brain (FACT-Br), Profile of Mood States, Mini-Mental Status Exam, Trail Making Test Parts A (TMT-A) and B (TMT-B), Digit Span Test, Modified Rey Osterrieth Complex Figure (ROCF), California Verbal Learning Test Part II, and the F-A-S Test. RESULTS: Of the 34 patients enrolled on study, 23 (68 %) completed 12 weeks of treatment and 19 (56 %) completed 24 weeks of treatment. There were significant improvements at 24 weeks in: executive function (TMT-B) (p = 0.007), attention/concentration (TMT-A) (p = 0.002), and non-verbal memory (ROCF-immediate/delayed recall) (p = 0.001/0.002), mood (p = 0.002), FACT-Br subscale (p = 0.001), and the FACT physical subscale (p = 0.003). CONCLUSIONS: Some improvement in quality of life and cognitive function were noted with Ginkgo biloba. However, treatment with Ginkgo biloba was associated with a high dropout rate.
UNLABELLED: Ginkgo biloba has been reported to improve cognitive function in older adults and patients with Alzheimer's disease and multi-infarct dementia. We conducted an open-label phase II study of this botanical product in symptomatic irradiated brain tumor survivors. Eligibility criteria included: life expectancy ≥30 weeks, partial or whole brain radiation ≥6 months before enrollment, no imaging evidence of tumor progression in previous 3 months, or stable or decreasing steroid dose, and no brain tumor treatment planned while on study. The Ginkgo biloba dose was 120 mg/day (40 mg t.i.d.) for 24 weeks followed by a 6-week washout period. Assessments performed at baseline, 12, 24 (end of treatment), and 30 weeks (end of washout) included KPS, Functional Assessment of Cancer Therapy-Brain (FACT-Br), Profile of Mood States, Mini-Mental Status Exam, Trail Making Test Parts A (TMT-A) and B (TMT-B), Digit Span Test, Modified Rey Osterrieth Complex Figure (ROCF), California Verbal Learning Test Part II, and the F-A-S Test. RESULTS: Of the 34 patients enrolled on study, 23 (68 %) completed 12 weeks of treatment and 19 (56 %) completed 24 weeks of treatment. There were significant improvements at 24 weeks in: executive function (TMT-B) (p = 0.007), attention/concentration (TMT-A) (p = 0.002), and non-verbal memory (ROCF-immediate/delayed recall) (p = 0.001/0.002), mood (p = 0.002), FACT-Br subscale (p = 0.001), and the FACT physical subscale (p = 0.003). CONCLUSIONS: Some improvement in quality of life and cognitive function were noted with Ginkgo biloba. However, treatment with Ginkgo biloba was associated with a high dropout rate.
Authors: V A Levin; W K A Yung; J Bruner; A Kyritsis; N Leeds; M J Gleason; K R Hess; C A Meyers; S A Ictech; E Chang; M H Maor Journal: Int J Radiat Oncol Biol Phys Date: 2002-05-01 Impact factor: 7.038
Authors: G M Kiebert; D Curran; N K Aaronson; M Bolla; J Menten; E H Rutten; E Nordman; M E Silvestre; M Pierart; A B Karim Journal: Eur J Cancer Date: 1998-11 Impact factor: 9.162
Authors: Edward G Shaw; Robin Rosdhal; Ralph B D'Agostino; James Lovato; Michelle J Naughton; Michael E Robbins; Stephen R Rapp Journal: J Clin Oncol Date: 2006-03-20 Impact factor: 44.544
Authors: Steven T DeKosky; Jeff D Williamson; Annette L Fitzpatrick; Richard A Kronmal; Diane G Ives; Judith A Saxton; Oscar L Lopez; Gregory Burke; Michelle C Carlson; Linda P Fried; Lewis H Kuller; John A Robbins; Russell P Tracy; Nancy F Woolard; Leslie Dunn; Beth E Snitz; Richard L Nahin; Curt D Furberg Journal: JAMA Date: 2008-11-19 Impact factor: 56.272
Authors: Beth E Snitz; Ellen S O'Meara; Michelle C Carlson; Alice M Arnold; Diane G Ives; Stephen R Rapp; Judith Saxton; Oscar L Lopez; Leslie O Dunn; Kaycee M Sink; Steven T DeKosky Journal: JAMA Date: 2009-12-23 Impact factor: 56.272
Authors: Eric L Chang; Jeffrey S Wefel; Kenneth R Hess; Pamela K Allen; Frederick F Lang; David G Kornguth; Rebecca B Arbuckle; J Michael Swint; Almon S Shiu; Moshe H Maor; Christina A Meyers Journal: Lancet Oncol Date: 2009-10-02 Impact factor: 41.316
Authors: Christina K Cramer; Tiffany L Cummings; Rachel N Andrews; Roy Strowd; Stephen R Rapp; Edward G Shaw; Michael D Chan; Glenn J Lesser Journal: Curr Treat Options Oncol Date: 2019-04-08
Authors: Christina K Cramer; Neil McKee; L Doug Case; Michael D Chan; Tiffany L Cummings; Glenn J Lesser; Edward G Shaw; Stephen R Rapp Journal: J Neurooncol Date: 2018-11-07 Impact factor: 4.130
Authors: Christina K Cramer; Natalie Alphonse-Sullivan; Scott Isom; Linda J Metheny-Barlow; Tiffany L Cummings; Brandi R Page; Doris R Brown; Arthur W Blackstock; Ann M Peiffer; Roy E Strowd; Stephen Rapp; Glenn J Lesser; Edward G Shaw; Michael D Chan Journal: J Cancer Res Clin Oncol Date: 2018-11-12 Impact factor: 4.553
Authors: Chiara D'Antonio; Antonio Passaro; Bruno Gori; Ester Del Signore; Maria Rita Migliorino; Serena Ricciardi; Alberto Fulvi; Filippo de Marinis Journal: Ther Adv Med Oncol Date: 2014-05 Impact factor: 8.168